CD68 and cancer: CD68 is a marker of TAMs, and its presence in the tumor stroma has been suggested to be a prognostic factor for worse survival in some cancer types.27–30 Thus, this finding supports the notion that combined JAK1 plus PI3Kδ inhibition may support the development of some aspects associated with a favorable TME by decreasing the presence of immunosuppressive TAMs.